论文部分内容阅读
目的:探讨重组人白介素-11治疗急性髓系白血病(AML)化疗后血小板减少的有效性和安全性。方法:分别选择21例患者43例次化疗为治疗组和对照组,治疗组化疗结束24h或血小板低于100×109/L时给予皮下注射重组人白介素-11 25μg.kg-1.d-1,观察患者化疗后血小板计数变化、输注血小板剂量和药物不良反应。结果:治疗组和对照组化疗后最低血小板计数和输注血小板次数差异无统计学意义(P>0.05)。血小板恢复至50×109/L的天数和恢复至100×109/L的天数差异有统计学意义(P<0.01),治疗组较对照组平均约提前2.5d。治疗组耐受性良好,观察到的不良反应有全身乏力、水肿、注射部位疼痛,其发生率均不到10%。结论:重组人白介素-11辅助治疗AML可以一定程度上缩短患者化疗后血小板低下持续的时间,且耐受性良好。
Objective: To investigate the efficacy and safety of recombinant human interleukin-11 in the treatment of acute myeloid leukemia (AML) after thrombocytopenia. Methods: Twenty-three patients in 21 patients were selected as the treatment group and the control group. The patients in the treatment group were given subcutaneous injection of recombinant human interleukin-11 (25μg.kg-1.d-1) 24h or platelet less than 100 × 109 / L The changes of platelet count, the platelet transfusion dose and adverse drug reactions were observed after chemotherapy. Results: There was no significant difference in the lowest platelet count and the number of transfusion platelets between the treatment group and the control group after chemotherapy (P> 0.05). There was a significant difference between the days of platelet recovery to 50 × 109 / L and the number of days of recovery to 100 × 109 / L (P <0.01), and the treatment group averaged about 2.5 days earlier than the control group. The treatment group was well tolerated. The observed adverse reactions were generalized weakness, edema and pain in the injection site, all of which were less than 10%. Conclusion: Recombinant human interleukin-11 adjuvant therapy of AML can shorten the duration of patients with post-chemotherapy platelet damage to a certain extent, and well tolerated.